PURPOSE: Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT. PATIENTS AND METHODS: A cohort of 538 patients with prostate cancer treated with ADT was genotyped for SLCO2B1 and SLCO1B3 single nucleotide polymorphisms (SNP). The biologic function of a SLCO2B1 coding SNP in transporting androgen was examined through biochemical assays. RESULTS: Three SNPs in SLCO2B1 were associated with time to progression (TTP) on ADT (P < .05). The differences in median TTP for each of these polymorphisms were about 10 months. The SLCO2B1 genotype, which allows more efficient import of androgen, enhances cell growth and is associated with a shorter TTP on ADT. Patients carrying both SLCO2B1 and SLCO1B3 genotypes, which import androgens more efficiently, exhibited a median 2-year shorter TTP on ADT, demonstrating a gene-gene interaction (P(interaction) = .041). CONCLUSION: Genetic variants of SLCO2B1 and SLCO1B3 may function as pharmacogenomic determinants of resistance to ADT in prostate cancer.
PURPOSE: Androgen deprivation therapy (ADT), an important treatment for advanced prostate cancer, is highly variable in its effectiveness. We hypothesized that genetic variants of androgen transporter genes, SLCO2B1 and SLCO1B3, may determine time to progression on ADT. PATIENTS AND METHODS: A cohort of 538 patients with prostate cancer treated with ADT was genotyped for SLCO2B1 and SLCO1B3 single nucleotide polymorphisms (SNP). The biologic function of a SLCO2B1 coding SNP in transporting androgen was examined through biochemical assays. RESULTS: Three SNPs in SLCO2B1 were associated with time to progression (TTP) on ADT (P < .05). The differences in median TTP for each of these polymorphisms were about 10 months. The SLCO2B1 genotype, which allows more efficient import of androgen, enhances cell growth and is associated with a shorter TTP on ADT. Patients carrying both SLCO2B1 and SLCO1B3 genotypes, which import androgens more efficiently, exhibited a median 2-year shorter TTP on ADT, demonstrating a gene-gene interaction (P(interaction) = .041). CONCLUSION: Genetic variants of SLCO2B1 and SLCO1B3 may function as pharmacogenomic determinants of resistance to ADT in prostate cancer.
Authors: Paul I W de Bakker; Noël P Burtt; Robert R Graham; Candace Guiducci; Roman Yelensky; Jared A Drake; Todd Bersaglieri; Kathryn L Penney; Johannah Butler; Stanton Young; Robert C Onofrio; Helen N Lyon; Daniel O Stram; Christopher A Haiman; Matthew L Freedman; Xiaofeng Zhu; Richard Cooper; Leif Groop; Laurence N Kolonel; Brian E Henderson; Mark J Daly; Joel N Hirschhorn; David Altshuler Journal: Nat Genet Date: 2006-10-22 Impact factor: 38.330
Authors: William K Oh; Julia Hayes; Carolyn Evan; Judith Manola; Daniel J George; Helen Waldron; Meaghan Donovan; John Varner; John Orechia; Beth Katcher; Diana Lu; Arthur Nevins; Renée L Wright; Lauren Tormey; James Talcott; Mark A Rubin; Massimo Loda; William R Sellers; Jerome P Richie; Philip W Kantoff; Jane Weeks Journal: Clin Genitourin Cancer Date: 2006-06 Impact factor: 2.872
Authors: Robert W Ross; William K Oh; Wanling Xie; Mark Pomerantz; Mari Nakabayashi; Oliver Sartor; Mary-Ellen Taplin; Meredith M Regan; Philip W Kantoff; Matthew Freedman Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Robert W Ross; Wanling Xie; Meredith M Regan; Mark Pomerantz; Mari Nakabayashi; Timothy J Daskivich; Oliver Sartor; Mary-Ellen Taplin; Philip W Kantoff; William K Oh Journal: Cancer Date: 2008-03-15 Impact factor: 6.860
Authors: Nima Sharifi; Akinobu Hamada; Tristan Sissung; Romano Danesi; David Venzon; Caitlin Baum; James L Gulley; Douglas K Price; William L Dahut; William D Figg Journal: BJU Int Date: 2008-06-04 Impact factor: 5.588
Authors: R Bruce Montgomery; Elahe A Mostaghel; Robert Vessella; David L Hess; Thomas F Kalhorn; Celestia S Higano; Lawrence D True; Peter S Nelson Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Akinobu Hamada; Tristan Sissung; Douglas K Price; Romano Danesi; Cindy H Chau; Nima Sharifi; David Venzon; Kenji Maeda; Keisuke Nagao; Alex Sparreboom; Hiroaki Mitsuya; William L Dahut; William D Figg Journal: Clin Cancer Res Date: 2008-06-01 Impact factor: 12.531
Authors: Tristan M Sissung; Sarah M Troutman; Tessa J Campbell; Heather M Pressler; Hyeyoung Sung; Susan E Bates; William D Figg Journal: Discov Med Date: 2012-01 Impact factor: 2.970
Authors: Manish Kohli; Shaun M Riska; Douglas W Mahoney; High S Chai; David W Hillman; David N Rider; Brian A Costello; Rui Qin; Jatinder Lamba; Deepak M Sahasrabudhe; James R Cerhan Journal: Mayo Clin Proc Date: 2012-03 Impact factor: 7.616
Authors: Mary-Ellen Taplin; Bruce Montgomery; Christopher J Logothetis; Glenn J Bubley; Jerome P Richie; Bruce L Dalkin; Martin G Sanda; John W Davis; Massimo Loda; Lawrence D True; Patricia Troncoso; Huihui Ye; Rosina T Lis; Brett T Marck; Alvin M Matsumoto; Steven P Balk; Elahe A Mostaghel; Trevor M Penning; Peter S Nelson; Wanling Xie; Zhenyang Jiang; Christopher M Haqq; Daniel Tamae; NamPhuong Tran; Weimin Peng; Thian Kheoh; Arturo Molina; Philip W Kantoff Journal: J Clin Oncol Date: 2014-10-13 Impact factor: 44.544